Abstract
Immunocompromised individuals are at high risk for life-threatening diseases, especially those caused by cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenovirus. Conventional therapeutics are primarily active only against CMV, and resistance is frequent. Adoptive transfer of polyclonal cytotoxic T lymphocytes (CTLs) specific for CMV or EBV seems promising, but it is unclear whether this strategy can be extended to adenovirus, which comprises many serotypes. In addition, the preparation of a specific CTL line for each virus in every eligible individual would be impractical. Here we describe genetic modification of antigen-presenting cell lines to facilitate the production of CD4+ and CD8+ T lymphocytes specific for CMV, EBV and several serotypes of adenovirus from a single cell culture. When administered to immunocompromised individuals, the single T lymphocyte line expands into multiple discrete virus-specific populations that supply clinically measurable antiviral activity. Monoculture-derived multispecific CTL infusion could provide a safe and efficient means to restore virus-specific immunity in the immunocompromised host.
Similar content being viewed by others
References
Chakrabarti, S. et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99, 4357–4363 (2002).
Chakrabarti, S. et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100, 1619–1627 (2002).
Bollard, C.M., Kuehnle, I., Leen, A., Rooney, C.M. & Heslop, H.E. Adoptive immunotherapy for posttransplantation viral infections. Biol. Blood Marrow Transplant. 10, 143–155 (2004).
Papadopoulos, E.B. et al. Infusions of donor leukocytes to treat Epstein-Barr virus–associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185–1191 (1994).
Heslop, H.E., Brenner, M.K. & Rooney, C.M. Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331, 679–680 (1994).
Rooney, C.M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus–induced lymphoma in allogeneic transplant recipients. Blood 92, 1549–1555 (1998).
Walter, E.A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038–1044 (1995).
Einsele, H. et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99, 3916–3922 (2002).
Riddell, S.R. et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238–241 (1992).
Cobbold, M. et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202, 379–386 (2005).
Peggs, K.S. et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362, 1375–1377 (2003).
Gustafsson, A. et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95, 807–814 (2000).
Heslop, H.E. et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2, 551–555 (1996).
Lion, T. et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 102, 1114–1120 (2003).
Leen, A.M. et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood 104, 2432–2440 (2004).
Heemskerk, B. et al. Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy. J. Virol. 77, 6562–6566 (2003).
Wang, Q., Strong, J. & Killeen, N. Homeostatic competition among T cells revealed by conditional inactivation of the mouse CD4 gene. J. Exp. Med. 194, 1721–1730 (2001).
Khanna, R. & Burrows, S.R. Role of cytotoxic T lymphocytes in Epstein-Barr virus–associated diseases. Annu. Rev. Microbiol. 54, 19–48 (2000).
Wagner, H.J. et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 103, 3979–3981 (2004).
Wadell, G., Hammarskjold, M-L., Winberg, G., Varsanyi, T.W. & Sundell, G. The genetic variability of adenoviruses. Ann. NY Acad. Sci. 354, 16–42 (1980).
Leen, A.M. et al. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 103, 1011–1019 (2004).
Smith, C.A., Woodruff, L.S., Rooney, C. & Kitchingman, G.R. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum. Gene Ther. 9, 1419–1427 (1998).
Gottschalk, S. et al. An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 97, 835–843 (2001).
Busson, P., Edwards, R.H., Tursz, T. & Raab-Traub, N. Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. J. Gen. Virol. 76, 139–145 (1995).
Bollard, C.M. et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus + Hodgkin's Disease. J. Exp. Med. 200, 1623–1633 (2004).
Bunde, T. et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med. 201, 1031–1036 (2005).
Wherry, E.J. et al. Homeostatic proliferation but not the generation of virus specific memory CD8 T cells is impaired in the absence of IL-15 or IL-15Rα. Adv. Exp. Med. Biol. 512, 165–175 (2002).
Myers, G.D. et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 36, 1001–1008 (2005).
Sili, U. et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocytes using lymphoblastoid cell lines for adoptive immunotherapy. J. Immunother. 26, 241–256 (2003).
Yotnda, P. et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 8, 930–937 (2001).
Rooney, C.M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345, 9–13 (1995).
Heim, A., Ebnet, C., Harste, G. & Pring-Akerblom, P. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J. Med. Virol. 70, 228–239 (2003).
Acknowledgements
We thank V. Torrano for research coordination; J. Gilbert for editorial assistance; T. Gotsolva and F. Jimenez for technical assistance; and T. Lopez and staff in the Good Manufacturing Practice facilities for assisting in CTL preparation and quality assurance. This work was supported in part by a Production Assistance for Cellular Therapies (contract NO1HB37163–C001) from the National Heart, Lung, and Blood Institute (to C.M.R and A.P.G), grants from the National Gene Vector Laboratories (NIH-NCRR U42 RR16578) and the General Clinical Research Center at Baylor College of Medicine (RR00188), a Doris Duke Distinguished Clinical Scientist award (to H.E.H.), the Amy Strelzer Manasevit Scholar Award (to C.M.B.), and an award from the Dana Foundation (to C.M.R. and A.M.L).
Author information
Authors and Affiliations
Contributions
This study was developed and designed by C.M.R., H.E.H., M.K.B. and C.M.B. The principal investigator on the clinical trial was C.M.B. A.M.L., U.S. and C.M.R. developed the new method for generating the tri-virus specific CTLs. G.D.M., A.M.L. and C.M.B. performed the PCR and immune reconstitution studies. R.A.K., G.C. and K.S.L. cared for the transplant subjects enrolled in this study. H.W. provided statistical support. A.P.G. and M.H.H. supervised C.T.L. preparation and quality assurance. C.-C.C. and J.J.M. provided advice and support for CMV PCR studies and immune monitoring. C.M.R., H.E.H., M.K.B., A.M.L. and C.M.B. contributed to the writing of the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Fig. 1
Effects of adenovirus-specific CTL in vivo. (PDF 229 kb)
Supplementary Fig. 2
Activity of polyclonal CTL line for a representative patient, sorted for both CD4+ and CD8+ T cells against CMV. (PDF 143 kb)
Supplementary Table 1
Virus-specific activity of CTL lines. (PDF 58 kb)
Supplementary Table 2
Epitopes recognized in each virus by multivirus-specific CTL compared to monospecific CTL. (PDF 58 kb)
Rights and permissions
About this article
Cite this article
Leen, A., Myers, G., Sili, U. et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12, 1160–1166 (2006). https://doi.org/10.1038/nm1475
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1475
- Springer Nature America, Inc.
This article is cited by
-
Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells
Gene Therapy (2023)
-
Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine
International Journal of Hematology (2021)
-
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential
Cancer Immunology, Immunotherapy (2020)